Five Prime Therapeutics

Five Prime Therapeutics is a biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Its product candidates include Bemarituzumab (FPA144), an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, and that induces antibody-dependent cellular cytotoxicity; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; FPA157, an anti-CCR8 antibody that is engineered to deplete CCR8-expressing intratumoral regulatory CD4+ T cells; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3, or TIM-3, antibody.